Terns Pharmaceuticals Inc TERN
At closeMay 15, 2026, 4:00 PM EDT
After hours · May 15, 4:00 PM ET
- YTD
- +31.06%
- 1 year
- +1,797.85%
- Market cap
- 6.12B
- EPS (ttm)
- -1.03
- YTD return
- +31.06%
- 1-year return
- +1797.85%
- Volume
- 6.33M
- Avg volume
- 4.84M
- Open
- 52.97
- Previous close
- 52.95
- Day's range
- 52.95 – 52.97
- 52-week range
- 7.87 – 53.19
- Beta
- -0.38
2Y +46.96 (+783.97%)
Key statistics
- Enterprise value
- 5.59B
- PEG ratio
- -7.37
- Price / sales
- 0.00
- Price / book
- 4.90
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -13.59%
Analyst view
- Strong buy0
- Buy0
- Hold6
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.26333.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 14, 2026 | Mar 31, 2026 | -0.30 | -0.26 | +0.04 | +13.33% |
| Mar 30, 2026 | Dec 31, 2025 | -0.29 | -0.25 | +0.04 | +13.79% |
| Nov 10, 2025 | Sep 30, 2025 | -0.30 | -0.27 | +0.03 | +10.00% |
| Aug 5, 2025 | Jun 30, 2025 | -0.28 | -0.26 | +0.02 | +7.14% |
| May 8, 2025 | Mar 31, 2025 | -0.29 | -0.26 | +0.03 | +10.34% |
| Mar 20, 2025 | Dec 31, 2024 | -0.30 | -0.24 | +0.06 | +20.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 27, 2026 | Oppenheimer | down | Outperform | Perform |
| Apr 14, 2026 | JP Morgan | main | Overweight | Overweight |
| Mar 31, 2026 | Truist Securities | down | Buy | Hold |
| Mar 30, 2026 | Barclays | down | Overweight | Equal-Weight |
| Mar 26, 2026 | Citizens | down | Market Outperform | Market Perform |
| Mar 26, 2026 | TD Cowen | down | Buy | Hold |
About Terns Pharmaceuticals Inc
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 59
- Website
- ternspharma.com
News
'Merck Starts Seven-Part High-Grade Bond Sale to Fund Terns Deal' - Bloomberg 
What's Going On With Merck Stock Tuesday? 
This United Natural Foods Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday 
This Mondelez Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday 
Broadcom To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday 
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday 
Henry Schein, Sanmina, Wingstop, Waters And Other Big Stocks Moving Higher On Tuesday 
12 Health Care Stocks Moving In Tuesday's Intraday Session 
Kenvue, IDEXX Laboratories, Freshpet And Other Big Stocks Moving Higher On Monday 
12 Health Care Stocks Moving In Monday's Intraday Session
Your note
Sign in to keep a note on TERN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BURROUGHS AMY LOUISE | Chief Executive Officer | Sale | Mar 15, 2026 | 297,295 |
| GENGOS ANDREW | Chief Financial Officer | Stock Award(Grant) | Jan 13, 2026 | 101,788 |
| GORDON CARL L | Director and Beneficial Owner of more than 10% of a Class of Security | Sale | Jul 15, 2024 | 0 |
| KURIAKOSE EMIL T. | Officer | Sale | Mar 31, 2026 | 105,673 |
| LU HONGBO B | Director | Purchase | Sep 11, 2024 | 0 |
| ORBIMED ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Jul 15, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.09% | 8,194,218 | 433.88M | Dec 30, 2025 |
| Morgan Stanley | 6.88% | 7,945,608 | 420.72M | Dec 30, 2025 |
| Adage Capital Partners GP L.L.C. | 4.80% | 5,550,000 | 293.87M | Dec 30, 2025 |
| Vanguard Group Inc | 4.78% | 5,523,948 | 292.49M | Dec 30, 2025 |
| Vivo Capital, LLC | 4.63% | 5,346,928 | 283.12M | Dec 30, 2025 |
| Vestal Point Capital, LP | 3.90% | 4,500,000 | 238.28M | Dec 30, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.76% | 3,184,983 | 168.64M | Dec 30, 2025 |
| iShares Trust-iShares Russell 2000 ETF | 2.01% | 2,320,931 | 122.89M | Mar 30, 2026 |
| LORD ABBETT SECURITIES TRUST-Lord Abbett Growth Leaders Fund | 1.38% | 1,588,735 | 84.12M | Jan 30, 2026 |
| SmallCap World Fund Inc | 0.92% | 1,060,000 | 56.13M | Dec 30, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.80% | 927,850 | 49.13M | Dec 30, 2025 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.73% | 839,458 | 44.45M | Feb 27, 2026 |